Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867003505742446592 |
|---|---|
| author | Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao |
| author_facet | Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao |
| collection | Wiley Open Access |
| contents | Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao Precision Radiation Oncology AbstractPurposeThis study aimed to examine the individualized neoadjuvant therapies for operable esophageal cancer.Methods and MaterialsData of 95,444 patients diagnosed with esophageal cancer between 2010 and 2017 were collected from the Surveillance, Epidemiology, and End Results database. The effectiveness of neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy (nCT), and surgery alone was compared in patients with stage II esophageal cancer. Patients with stage III disease were divided into “local invasive type” group (type I, T3N1M0, T4N0‐1M0) and “regional metastatic type” group (type II, T1‐2N2‐3M0) according to the tumor invasion pattern. The effectiveness of nCRT and nCT in different patterns was compared.ResultsIn 2,706 patients with stage II disease, a statistical difference was observed in the overall survival (OS) between nCRT (85.1%), nCT (3.0%), and surgery alone (11.9%, P<0.001, median OS (mOS): 54 vs 41 vs 24 months). Meanwhile, 3,303 patients with stage III disease who received nCRT were included in the propensity score matching. A statistical difference was observed in the OS between “Type I” (n = 217) and “Type II” (n = 217, P = 0.023, mOS: 45 VS 28 months). Among 93 patients with stage III receiving nCT, those with “Type II” (23.7%) showed a greater potential benefit from nCT than those with “Type I” (76.3%, P = 0.686, mOS: 51 vs 40 months).ConclusionsnCRT is recommended for stage II esophageal cancer. In patients with stage III, those with “local invasive type” may greatly benefit from nCRT, while those with “regional metastatic type” may greatly benefit from nCT. 10.1002/pro6.1249 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/pro6.1249 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_pro6_1249 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao Precision Radiation Oncology Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis Xingyu Zhou Jiao Xue Long Chen Songbin Qin Qi Zhao Precision Radiation Oncology AbstractPurposeThis study aimed to examine the individualized neoadjuvant therapies for operable esophageal cancer.Methods and MaterialsData of 95,444 patients diagnosed with esophageal cancer between 2010 and 2017 were collected from the Surveillance, Epidemiology, and End Results database. The effectiveness of neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy (nCT), and surgery alone was compared in patients with stage II esophageal cancer. Patients with stage III disease were divided into “local invasive type” group (type I, T3N1M0, T4N0‐1M0) and “regional metastatic type” group (type II, T1‐2N2‐3M0) according to the tumor invasion pattern. The effectiveness of nCRT and nCT in different patterns was compared.ResultsIn 2,706 patients with stage II disease, a statistical difference was observed in the overall survival (OS) between nCRT (85.1%), nCT (3.0%), and surgery alone (11.9%, P<0.001, median OS (mOS): 54 vs 41 vs 24 months). Meanwhile, 3,303 patients with stage III disease who received nCRT were included in the propensity score matching. A statistical difference was observed in the OS between “Type I” (n = 217) and “Type II” (n = 217, P = 0.023, mOS: 45 VS 28 months). Among 93 patients with stage III receiving nCT, those with “Type II” (23.7%) showed a greater potential benefit from nCT than those with “Type I” (76.3%, P = 0.686, mOS: 51 vs 40 months).ConclusionsnCRT is recommended for stage II esophageal cancer. In patients with stage III, those with “local invasive type” may greatly benefit from nCRT, while those with “regional metastatic type” may greatly benefit from nCT. 10.1002/pro6.1249 http://creativecommons.org/licenses/by/4.0/ |
| title | Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis |
| topic | Precision Radiation Oncology |
| url | https://onlinelibrary.wiley.com/doi/10.1002/pro6.1249 |